Featured Symposia

Sunday 23 October 2022

10:15–11:45NEAT ID Symposium and Updates
Workshop organised by the NEAT ID Foundation

NEAT ID Symposium and Updates will focus on the history of NEAT ID, the future,
we will be presenting Data, discussing ongoing and upcoming projects and our
NEAT ID Integration Grant initiative. The session will take place in Carron 2 of the SEC and will include the following presentations and faculty:

Welcome: Christine Katlama, Paris, France and Carlo Giaquinto, Padova, Italy
Introduction: Anton Pozniak, London, UK
NEAT ID background: Stefano Vella, Rome, Italy
PIONEER: Marta Boffito, London, UK
PrEP survey: Jean-Michel Molina, Paris, France
WISARD w48 data: TBC
NEAT 22 Sub studies – Weight gain: Esteban Martinez, Barcelona, Spain
NEAT ID studies and publications: Georg Behrens, Hannover, Germany
NEAT ID new studies: Stephane de Wit, Brussels, Belgium
NEAT ID integration grants: Juergen Rockstroh, Bonn, Germany
Closing remarks: Anton Pozniak

10:15–12:15STEPS 8: A Community Initiative to Design the Pathway to a
Long-Term Remission of HIV Infection

Workshop organised by the European AIDS Treatment Group (EATG)

The 8th STEPS HIV Cure Community-led Workshop will take place in Carron 1 at the SEC. If you are interested in knowing more about HIV cure-related research in
Europe from a community perspective, you are invited to apply to the 8th community meeting focused on HIV cure strategies, therapeutic vaccines and innovative approaches for a long-term remission of HIV infection. The provisional programme is
as follows:

Welcome and introduction
Brian West,
Edinburgh, UK

Overview of HIV cure/remission research with different approaches
Casper Rokx,
Rotterdam, The Netherlands

Approaches to remission and European research in therapeutic vaccines
Jean-Daniel Levlievre,
Paris, France

Community perspective on cure/remission research
Simon Collins,
London, UK

Q&A session

Conclusion and follow up
Brian West

12:30–13:30Resistance is Futile: Achieving and Maintaining HIV Viral Suppression
A CME-Accredited symposium organised by PeerVoice with educational
funding provided by MSD

12:30–12:35Welcome and introductions
Anton Pozniak,
London School of Hygiene and Tropical Medicine, and Chelsea
and Westminster Hospital, London, UK

12:35–12:50HIV drug resistance profiles and cross-resistance patterns: What we know
to date

Panel discussion led by Anton Pozniak, joined by Anna Maria Geretti, University
of Rome Tor Vergata, Rome, Italy; and King’s College London, London, UK;
and Andrew Ustianowski, University of Manchester, North Manchester General
Hospital, Manchester, UK

12:50–13:05Avoiding resistance in people living with HIV who are treatment-naive:
How would you manage these people?

13:05–13:20Circumventing resistance in people living with HIV who are virologically
suppressed: How would you manage these people?

13:20–13:30“Ask the faculty” and take-home messages

14:15–15:15The Devil Wears GP120
Symposium organised by Virology Education

Chair:Jonathan Schapiro, National Hemophilia Center, Sheba Medical Center,
Tel Aviv, Israel

Jonathan Schapiro

14:20–14:35Immune dysregulation: A remaining challenge in HIV medicine
John Thornhill,
Imperial College London, London, UK

14:35–14:50Clinical data from the GP120 inhibitor temsavir and its relevance to immune
reconstitution and HIV associated inflammation

Georg Behrens, Department for Clinical Immunology and Rheumatology,
Hannover Medical School, Hannover, Germany

14:50–15:05Temsavir blocks HIV-1 soluble GP120-induced immunomodulatory activities
Andrés Finzi,
Université de Montréal, Montréal, Canada

15:05–15:15Discussion and close

15:30–16:30Supporting Patient Goals: For Now. For the Future. For Every Step
Promotional Symposium, Gilead Sciences

Chair:Sorana Segal-Maurer, The Dr James J Rahal Jr Division of Infectious
Diseases, New York-Presbyterian Queens; and Clinical Medicine,
Weill Cornell Medical College, Cornell University, New York, NY, USA

15:30–15:35Welcome and Introduction
Sorana Segal-Maurer

15:35–15:45For now: Navigating daily life
Panel discussion featuring Sorana Segal-Maurer, joined by Marta Boffito, Chelsea
and Westminster Hospital and Imperial College London, London, UK; and
Christopher Spinner, Interdisciplinary HIV Centre (IZAR), University Hospital Klinikum
Rechts der Isar, and Technical University Munich, Munich, Germany

15:45–15:55For the future: Simplicity, tolerability, and reliability
Panel discussion: All

15:55–16:10For every step: What does long-term treatment success look like?
Panel discussion: All

16:10–16:20Live Q&A

16:20–16:30Meeting close
Sorana Segal-Maurer

Monday 24 October 2022

13:00–14:00Quality of Life Matters: A Conversation with the Experts on How to
Reach the 4th “90”

Symposium sponsored by Merck Sharp & Dohme

Chair:Marta Boffito, Chelsea and Westminster Hospital and Imperial
College London, London, UK

Marta Boffito

13:05–13:15What`s keeping us from reaching the 4th “90”? Unmet needs with current
HIV Treatment
Marta Boffito

13:15–13:45Beyond viral suppression: Practical management of current issues related
to HIV Treatment (Interactive cases discussion)
Andrew Ustianowski, Regional Infection Unit, North Manchester General Hospital,
Manchester, UK
Jürgen Rockstroh, University of Bonn, Department of Medicine, Bonn, Germany

Moderator: Marta Boffito

13:45–14:00Q&A and Close
Marta Boffito

17:30–19:00Individualised Care for Individual People
Promotional symposium sponsored by ViiV Healthcare

Chair:Jean Van Wyk, Global Medical, ViiV Healthcare

17:30–17:45HIV care is individual care
Jean Van Wyk

17:45–18:10Where do you start in naïve? Discussion on early optimisation
Marta Boffito,
Chelsea and Westminster Hospital and Imperial College London,
London, UK and
Cátia Caldas, Centro Hospitalar Universitário São João, Porto, Portugal

18:10–18:35Long acting injectable: addressing unmet needs in the real world
Marta Boffito
and Sebastian Noe, MVZ München am Goetheplatz, Munich, Germany

18:35–19:00Panel Q&A and close

Tuesday 25 October 2022

08:30–09:30Breaking Barriers In HIV Treatment®: First-In-Class Capsid Inhibitor
for Adults With HIV Who Are Heavily Treatment-Experienced (HTE)

Promotional symposium, Gilead Sciences

Chair:Jürgen Rockstroh, HIV Outpatient Clinic, University of Bonn,
Bonn, Germany

08:30–08:33Welcome and Introduction
Jürgen Rockstroh

08:33–08:40What does it mean to be heavily treatment-experienced (HTE)?
Jürgen Rockstroh

08:40–08:50Introduction to lenacapavir, a first-in-class capsid inhibitor
Tomas Cihlar,
Virology Research, Gilead Sciences, Foster City, CA, USA

08:50–09:00Learnings from the CAPELLA trial in HTE people living with HIV with
multi-drug resistance
Chloe Orkin,
Queen Mary University of London and Barts Health NHS Trust,
London, UK

09:00–09:15Best-practice for clinical management of people living with HIV who are HTE


09:25–09:30Conclusions and thanks
Jürgen Rockstroh

12:45–13:45Lessons Learned on Long-Acting ART: Implementation Insights
from European Pioneers

An independent medical education symposium provided by Clinical Care Options
and supported by an educational grant from ViiV Healthcare

Program Director: Celia Jonsson-Oldenbüttel, MVZ München am Goetheplatz
Munich, Germany

Celia Jonsson-Oldenbüttel

12:50–13:35Panel Discussion
The panel will share their experiences and insights in four key areas:
Patient candidacy, Administering LA-ART, Clinic infrastructure, What the
future holds

Stephane De Wit, Saint-Pierre University Hospital, Brussels, Belgium
Eric Florence, University Hospital / Institute of Tropical Medicine, Antwerp, Belgium
Mireia SantaCreu Guerrero, Hospital Universitario 12 de Octubre, Madrid, Spain
Laurence Slama, Hôtel Dieu Hospital, APHP Paris, France
Tom, Patient receiving long-acting ART

13:35–13:45Q&A session

17:30–18:30Beyond a One-size-fits-all Approach: Considerations From
Clinical Cases

Symposium sponsored by Janssen Pharmaceuticals

17:30–17:36Individualising treatment: Introduction
Alan Winston,
HIV and Genitourinary Medicine, Imperial College; and St Mary’s
Hospital, London, UK

Perspectives from physicians: Interactive case study reviews
Alan Winston,
joined by:
Marta Boffito, Clinical Research Facility, Chelsea and Westminster Hospital; and Imperial College, London, UK
Joseph Gathe, HCA Houston Healthcare Medical Center, Houston, TX;
and Infectious Diseases Society of America (IDSA), USA
Ignacio Perez Valero, Infectious Diseases Service, Reina Sofia University Hospital,
Córdoba, Spain; and Maimónides Institute for Biomedical Research (IMIBIC)

17:36–17:45Representing PLHIV: Rapid initiation considerations in a re-presenter

17:45–17:52Minding PLHIV: Exploring mental health issues in a late presenter

17:52–17:59Interactions with PLHIV: Management of DDIs in an elderly late presenter

17:59–18:23Panel discussion

Perspectives from PLHIV: Closing thoughts
Mario Cascio,
European AIDS Treatment Group (EATG), Italy

18:23–18:30Understanding PLHIV: Individualised HIV management